Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541785 | 1.00 | SYK (0.74) | SYKATMCTRB1APPMAPT | |
| SCHEMBL6310853 | 0.95 | SYK (0.82) | SYKATMCTRB1APPMAPT | |
| SCHEMBL6310847 | 0.95 | SYK (0.82) | SYKATMCTRB1APPMAPT | |
| SCHEMBL6310843 | 0.95 | SYK (0.82) | SYKATMCTRB1APPMAPT | |
| SCHEMBL14497009 | 0.90 | SYK (0.74) | SYKATMCTRB1APPMAPT | |
| SCHEMBL28668267 | 0.90 | SYK (0.74) | SYKATMCTRB1APPMAPT | |
| SCHEMBL30489620 | 0.90 | SYK (0.74) | SYKATMCTRB1APPMAPT | |
| SCHEMBL15159987 | 0.90 | SYK (0.64) | SYKATMCTRB1APPMAPT | |
| SCHEMBL28663877 | 0.89 | SYK (0.73) | SYKATMCTRB1APPMAPT | |
| SCHEMBL30489676 | 0.89 | SYK (0.73) | SYKATMCTRB1APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181206-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8598170-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2456762-B1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-01 | — | — | US | disclosed |
| US-8372984-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | SYK 1761/4885ATM 4766/4885CTRB1 1123/4885 |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | SYK 1761/4885ATM 4766/4885CTRB1 1123/4885 |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | SYK 1761/4885ATM 4766/4885CTRB1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.